Patent information
IP India · live recordApplication number
202317069526
Filing date
16 October 2023
Status
Application Awaiting Examination
Publication number
36/2024
Publication type
INA
Invention field
Chemical
Abstract
The present disclosure relates to a pharmaceutical composition in the form of an orally deliverable liquid composition comprising tasipimidine, or a pharmaceutically acceptable salt thereof, as an active ingredient and to the use thereof in the treatment and prevention of a disorder, condition or disease where an alpha2A agonist is indicated to be useful, for example, for use as a sedative or analgesic agent, and for use in the treatment of anxiety or agitation. The composition is stable at the pH range from about 2.0 to about 5.0.
Applicants
1Finland
ORION CORPORATION
Orionintie 1
02200 Espoo
Inventors
4Finland
KUJALA, Johannac/o ORION CORPORATION
P.O.Box 65
02101 Espoo
Finland
LEHTISALO, Jennic/o ORION CORPORATION
P.O.Box 65
02101 Espoo
Finland
SALMIA, Jukkac/o ORION CORPORATION
P.O.Box 65
02101 Espoo
Finland
SINERVO, Kaic/o ORION CORPORATION
P.O.Box 65
02101 Espoo
Documents
Sign in to openApplication documents
1
202317069526-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [16-10-2023(online)].pdf
16 Oct 2023
2
202317069526-STATEMENT OF UNDERTAKING (FORM 3) [16-10-2023(online)].pdf
16 Oct 2023
3
202317069526-FORM 1 [16-10-2023(online)].pdf
16 Oct 2023
4
202317069526-DECLARATION OF INVENTORSHIP (FORM 5) [16-10-2023(online)].pdf
16 Oct 2023
5
202317069526-COMPLETE SPECIFICATION [16-10-2023(online)].pdf
16 Oct 2023
6
202317069526-FORM-26 [27-12-2023(online)].pdf
27 Dec 2023
7
202317069526-Proof of Right [18-03-2024(online)].pdf
18 Mar 2024
8
202317069526-FORM 3 [18-03-2024(online)].pdf
18 Mar 2024
9
202317069526-FORM 18 [24-12-2024(online)].pdf
24 Dec 2024